In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia

Research output: Contribution to journalArticle


Leukemic cells from 85 children with newly diagnosed precursor B-lineage ALL were tested for in vitro drug sensitivity to a panel of anti-cancer drugs. Minimal residual disease (MRD) was measured by RQ-PCR. There was a significant correlation between MRD day 29 and in vitro sensitivity to prednisolone (p < 0.001) and doxorubicin (p = 0.01 7), drugs administered during induction therapy. In patients with t(12;21) (n = 20), in vitro sensitivity to doxorubicin was an independent factor for MRD <0.1% (p = 0.031; R-2 = 0.66). Thus, data show that in vitro drug sensitivity at diagnosis is correlated to cell kill during induction therapy as measured by MRD day 29. (C) 2008 Elsevier Ltd. All rights reserved.


  • Gudmar Lonnerholm
  • Ingrid Thorn
  • Christer Sundstrom
  • Britt-Marie Frost
  • Jonas Abrahamsson
  • Mikael Behrendtz
  • Jesper Heldrup
  • Stefan Jacobsson
  • AiHong Li
  • Tor Olofsson
  • Anna Porwit
  • Stefan Soderhall
  • Rolf Larsson
  • Erik Forestier
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology


  • Doxorubicin, Prednisolone, 21), t(12, MRD, In vitro drug resistance, Acute lymphoblastic leukemia, Childhood
Original languageEnglish
Pages (from-to)46-53
JournalLeukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis
Issue number1
Publication statusPublished - 2009
Publication categoryResearch